SEC filing · 8-K

Ultragenyx Pharmaceutical Inc.: Material agreement

Ultragenyx entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash.

Filed October 7, 2026

Positive for the company

What happened

On October 6, 2026, Ultragenyx agreed to sell its Rare Pediatric Disease Priority Review Voucher to a buyer for $210 million in cash.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Ultragenyx Pharmaceutical Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.